{
    "eid": "2-s2.0-84959357825",
    "title": "Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by prior treatment",
    "cover-date": "2016-02-11",
    "subject-areas": [
        {
            "$": "Immunology",
            "@code": "2403"
        },
        {
            "$": "Biochemistry",
            "@code": "1303"
        },
        {
            "$": "Hematology",
            "@code": "2720"
        },
        {
            "$": "Cell Biology",
            "@code": "1307"
        }
    ],
    "keywords": [],
    "authors": [
        "Paul G. Richardson"
    ],
    "citedby-count": 108,
    "ref-count": 20,
    "ref-list": [
        "Improved survival in multiple myeloma and the impact of novel therapies",
        "Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients",
        "Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study",
        "Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges",
        "Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma",
        "Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial",
        "Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation",
        "A phase 2 study of Bortezomib in relapsed, refractory myeloma",
        "Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma",
        "Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma",
        "PANORAMA 2: Panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma",
        "Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma",
        "A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma",
        "Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial",
        "Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study",
        "Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: A UK cross-sectional survey",
        "Importance of achieving a complete response in multiple myeloma, and the impact of novel agents",
        "Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma",
        "Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes",
        "Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma"
    ],
    "affiliation": [
        {
            "affiliation-city": "Seongnam",
            "affilname": "Gachon University",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Siriraj Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Warsaw",
            "affilname": "Medical University of Warsaw",
            "affiliation-country": "Poland"
        },
        {
            "affiliation-city": "Alexandria",
            "affilname": "Alexandria University",
            "affiliation-country": "Egypt"
        },
        {
            "affiliation-city": "Athens",
            "affilname": "National and Kapodistrian University of Athens",
            "affiliation-country": "Greece"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nantes",
            "affilname": "CHU de Nantes",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Pamplona",
            "affilname": "Cl\u00ednica Universidad de Navarra",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Rueil-Malmaison",
            "affilname": "Novartis Pharma S.A.S.",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Shanghai",
            "affilname": "Changzheng Hospital",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Wurzburg",
            "affilname": "Julius-Maximilians-Universit\u00e4t W\u00fcrzburg",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Ankara",
            "affilname": "Ankara \u00dcniversitesi",
            "affiliation-country": "Turkey"
        },
        {
            "affiliation-city": "Cambridge",
            "affilname": "Harvard University",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Basel",
            "affilname": "Novartis International AG",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Kiel",
            "affilname": "Universit\u00e4tsklinikum Schleswig-Holstein Campus Kiel",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Vila Buarque",
            "affilname": "Irmandade da Santa Casa de Misericordia de Sao Paulo",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "Atlanta",
            "affilname": "Emory University",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Seoul",
            "affilname": "Seoul National University College of Medicine",
            "affiliation-country": "South Korea"
        }
    ],
    "funding": [
        "National Cancer Institute",
        "National Cancer Institute"
    ]
}